Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales

International Journal of Impotence Research volume 16, pages 527–530 (2004)Cite this article

Abstract

We assess the impact of introduction of sildenafil on alprostadil injection and penile implant surgery for the treatment of erectile dysfunction (ED) at our institution and in Taiwan. The data of national sales of sildenafil, alprostadil injection and penile implant were provided by industry companies. In the meanwhile, we analyzed the users of the above-mentioned three treatments at our institution. The national sales of sildenafil grew 136% from 0.8 million tablets in 1999 to 1.6 million tablets in 2002, while those of alprostadil injection dropped 33% after the marketing of sildenafil and of penile implant dropped 40% after the marketing of alprostadil injection and sildenafil. The market share of drugstores for sildenafil rose from 41% in 1999 to 72% in 2002. The trend of sales of sildenafil at our institution was similar to that of national sales from hospitals. Mean age of the sildenafil new users was becoming younger in the past 4 y (P<0.001). Of the new users of alprostadil injection and the recipients of penile implant, the commonest age group shifted from the range of 60–69 y before the launch of sildenafil to that of over 70 y after (P<0.05). In conclusion, the introduction of sildenafil has prompted more men as well as younger men with ED to seek treatment. Part of the roles of alprostadil injection and penile implants in this field are substituted by sildenafil and the commonest age group of their users becomes older than before.

This is a preview of subscription content, access via your institution

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1
Figure 2
Figure 3
Figure 4

References

  1. Krane RJ . Changes in ED therapy in the Viagra era. World J Urol 2001; 19: 23–24.

    Article  CAS  Google Scholar 

  2. Carson CC et al. The efficacy of sildenafil citrate (Viagra®) in clinical populations: an update. Urology 2002; 60 (Suppl 2): 12–27.

    Article  Google Scholar 

  3. Padma-Nathan H et al. A 4-year update on the safety of sildenafil citrate (Viagra®). Urology 2002; 60 (Suppl 2): 67–90.

    Article  Google Scholar 

  4. Wysowski DK, Swann J . Use of medications for erectile dysfunction in the United States, 1996 through 2001. J Urol 2003; 169: 1040–1042.

    Article  Google Scholar 

  5. Wilson EC et al. The cost to the United Kingdom National Health Service of managing erectile dysfunction: the impact of sildenafil and prescribing restrictions. Pharmacoeconomics 2002; 20: 879–889.

    Article  Google Scholar 

  6. Montorsi F et al. Treatment satisfaction in patients with erectile dysfunction switching from prostaglandin E(1) intracavernosal injection therapy to oral sildenafil citrate. Int J Impot Res 2003; 15: 444–449.

    Article  CAS  Google Scholar 

  7. Jarow JP, Burnett AL, Geringer AM . Clinical efficacy of sildenafil citrate based on etiology and response to prior treatment. J Urol 1999; 162: 722–725.

    Article  CAS  Google Scholar 

  8. Jiann BP et al. What we learn about sildenafil in the treatment of erectile dysfunction from 3-year clinical practice. Int J Impot Res 2003; 15: 412–417.

    Article  Google Scholar 

  9. Seftel AD . Erectile dysfunction in the elderly: epidemiology, etiology and approaches to treatment. J Urol 2003; 169: 1999–2007.

    Article  CAS  Google Scholar 

  10. Feldman HA et al. Impotence and its medical and psychosocial correlates: results of the Massachusetts male aging study. J Urol 1994; 151: 54–61.

    Article  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Division of Urology, Department of Surgery, Kaohsiung Veterans General Hospital, Kaohsiung, Taiwan

    B-P Jiann & C-C Yu

  2. Department of Urology, Yuan's General Hospital, Kaohsiung, Taiwan

    C-C Su

Authors
  1. B-P Jiann
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. C-C Yu
    View author publications

    You can also search for this author in PubMed Google Scholar

  3. C-C Su
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to C-C Yu.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Jiann, BP., Yu, CC. & Su, CC. Impact of introduction of sildenafil on other treatment modalities for erectile dysfunction: a study of nationwide and local hospital sales. Int J Impot Res 16, 527–530 (2004). https://doi.org/10.1038/sj.ijir.3901259

Download citation

  • Received:

  • Revised:

  • Accepted:

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/sj.ijir.3901259

Keywords

  • sildenafil
  • alprostadil
  • penile implant
  • erectile dysfunction
  • trend

This article is cited by

Search

Advanced search

Quick links